Literature DB >> 7084287

Clinical pharmacology of benoxaprofen.

A S Ridolfo, R H Carmichael, K A DeSante, R F Bergstrom, F W Rockhold, J F Nash, S E Fineberg.   

Abstract

Eating does not modify benoxaprofen blood concentrations. Combining benoxaprofen with tolbutamide does not significantly change plasma glucose, insulin, or tolbutamide concentrations. Probenecid, by blocking renal tubular secretion of benoxaprofen, increases the benoxaprofen half-life and decreases its renal clearance and urinary excretion. Excretion rate is halved in patients with severe renal impairment. Hemodialysis inefficiently lowers benoxaprofen plasma concentrations. Neither glomerular nor renal tubular function is affected by benoxaprofen, even after five years of therapy. The incidence in urine of microscopic spheroids (benoxaprofen glucuronide complexes) is related to urinary drug concentration and osmolality; increasing the fluid intake decreases incidence.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7084287

Source DB:  PubMed          Journal:  Eur J Rheumatol Inflamm        ISSN: 0140-1610


  3 in total

1.  Benoxaprofen inhibits the adhesion of human monocytes to cultured vascular endothelium.

Authors:  K A Brown; J Ferrie; B Wilbourn; D C Dumonde
Journal:  Agents Actions       Date:  1989-08

2.  Influence of probenecid on the urinary excretion rates of the diastereomeric benoxaprofen glucuronides.

Authors:  H Spahn; S Iwakawa; L Z Bevet; E T Lin
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Oct-Dec       Impact factor: 2.441

3.  Procedures to characterize in vivo and in vitro enantioselective glucuronidation properly: studies with benoxaprofen glucuronides.

Authors:  H Spahn; S Iwakawa; E T Lin; L Z Benet
Journal:  Pharm Res       Date:  1989-02       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.